Urine Adiponectin Concentration in Prediction of Contrast Induced Nephropathy

• Conditions: Myocardial Ischemia

• Registration Number: NCT01372891
• Lead Sponsor: Xijing Hospital

Brief Summary

The present study is to determine the ability of urinary total adiponectin and its isoforms excretion in the prediction of contrast induced nephropathy (CIN) in the patients undergoing PCI.

Detailed Description

Contrast induced nephropathy (CIN) is a severe complication after percutaneous coronary intervention (PCI). CIN is responsible for approximately genic renal insufficiency and is the third cause of hospital-acquired renal failure and the injury of endothelial of renal tubule is responsible for the CIN. However markers reliably identifying CIN in the patients undergoing PCI are rare. Adiponectin is a 30-kDa adipocyte-derived vasoactive peptide closely linked to components of the metabolic syndrome. Recent study demonstrates that the quantification of urinary adiponectin excretion appears to be an independent indicator of vascular damage potentially identifying an increased risk for vascular events. Therefore, the investigators presume that the adiponectin excretion may predict the incidence of the CIN. The present study is to determine the ability of urinary total adiponectin and its isoforms excretion in the prediction of CIN in the patients undergoing PCI.

Study Timeline

• Study Start: 2010-04
• Study First Submitted: 2011-06-10
• Study First Submitted QC: 2011-06-13
• Study First Posted: 2011-06-14
• Status Verified: 2011-11
• Last Update Submitted: 2011-11-21
• Last Update Posted: 2011-11-22
• Primary Completion: 2013-04
• Study Completion: 2014-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 400

Inclusion Criteria

• All patients > 18 of age who are undergoing elective PCI and are able to give informed consent are eligible for study.

Exclusion Criteria

• The end-stage renal failure
• The patients who are relieving dialysis

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
increase in SCr 0.5 mg/dL(44.2 mol/L) from baseline	3 days	samples will be collected at 24, 48 and 72 hours after PCI

Secondary Outcome Measures

Name	Time	Method
a 25% increase in SCr from baseline	3 days	samples will be collected at 24, 48 and 72 hours after PCI.

Trial Locations

Locations (1)

Xijing Hospital; 🇨🇳 Xi'an, Shaanxi, China